Sernova Corp. (TSE:SVA - Get Free Report) dropped 2.9% during mid-day trading on Thursday . The stock traded as low as C$0.17 and last traded at C$0.17. Approximately 135,769 shares were traded during mid-day trading, a decline of 10% from the average daily volume of 151,625 shares. The stock had previously closed at C$0.17.
Sernova Stock Performance
The company has a current ratio of 0.32, a quick ratio of 18.11 and a debt-to-equity ratio of -4.40. The company has a market cap of C$55.52 million, a P/E ratio of -1.59 and a beta of 1.35. The firm's fifty day moving average price is C$0.19 and its 200-day moving average price is C$0.20.
Sernova Company Profile
(
Get Free Report)
Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. A bio-hybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sernova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sernova wasn't on the list.
While Sernova currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
